Skip to Content

'
Francesco Turturro, M.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1982 University of Bari Medical School, Bari, Italy, MD, Summa cum lsude, Internal Medicine and Hematology

Postgraduate Training

1/1995-6/1997 Clinical Fellowship, Hematology Oncology, University of Kentucky, Lexington, KY, K. Foon M.D.
6/1992-1/1995 Clinical Residency, Internal Medicine, University of Kentucky Medical School, Lexington, KY, R. Lightfoot, M.D.
7/1986-6/1989 Research Fellowship, Atherosclerosis and Lipoprotein Metabolism, Baylor College of Medicine, Houston, TX, Antonio M. Gotto, Jr.
6/1985-5/1986 Visiting Investigator, Molecular Biology, University of Bari, Bari, Italy, Italy, Professor Cecilia Saccone
9/1982-9/1985 Clinical Residency, Gerontology and Geriatrics, University of Bari Medical School, Bari, Italy, Italy, Professor Alfredo Tursi

Board Certifications

2008 Board of Medical Oncology

Experience/Service

Academic Appointments

Professor, Medicine and Molecular Cellular Physiology, Louisiana State University Health Science Center, Shreveport, LA, 7/2009-6/2011
Director, Blood and Stem Cell Transplant Hematological Malignancy, Louisiana State University Health Science Center, Shreveport, LA, 7/2007-6/2011
Director, Clinical Translational Research, Louisiana State University Health Science Center, Shreveport, LA, 2007-2011
Associate Professor, Internal Medicine, Hematology Oncology, Louisiana State University Health Science Center, Shreveport, LA, 5/2002-6/2009
Director of Research, Internal Medicine, University of Iowa Affiliated Program, Des Moines, IA, 10/2001-4/2002
Chief, Hematology Oncology, VA Central Iowa Health Care System, Des Moines, IA, 7/1997-5/2002
Clinical Assistant Professor, Internal Medicine, University of Iowa Affiliated Program, Des Moines, IA, 7/1997-5/2002
Instructor, Medicine, Div. of Atherosclerosis and Lipid Metabolism, Baylor College of Medicine, Houston, TX, 7/1989-6/1990
Investigator, Lipid and LipoproteinResearch, University of Bari Medical School, Bari, Italy, Italy, 9/1982-6/1986

Other Appointments/Responsibilities

Clinical Staff Scientist, Stoddard Research Cancer Institute, Des Moines, IA, 7/1997-5/2002
Assistant Chief Geriatric Medicine and Long Term Care, Hospital Clinica San Giovanni, Bari, Italy, Italy, 7/1990-6/1992
Instructor on Leave of Absence, Baylor College of Medicine, Houston, TX, 7/1990-6/1992

Honors and Awards

2010 100 Best Doctors in the Urban Area, Shreveport Bossier Magazine
2000 Excellence in Teaching Evidence Based Medicine, Des Moines Internal Medicine Residency
1990 Henry Christian Memorial Award for Outstanding Abstract in, American Federation for Clinical Research

Selected Publications

Peer-Reviewed Original Research Articles

1. Khouri IF, Wei W, Korbling M, Turturro F, Ahmed S, Alousi A, Anderlini P, Ciurea S, Jabbour E, Oran B, Popat UR, Rondon G, Bassett RL, Gulbis A. BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. Blood 124(14):2306-12, 10/2014. e-Pub 8/2014. PMID: 25145344.
2. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166(6):891-901, 9/2014. e-Pub 6/2014. PMID: 24943107.
3. Sniegowski MC, Roberts D, Bakhoum M, Mc Laughlin P, Yin VT, Turturro F, Esmaeli B. Ocular adnexal lymphoma: validation of American Joint Committee on Cancer seventh edition staging guidelines. Br J Ophthalmol 98(9):1255-60, 9/2014. e-Pub 4/2014. PMID: 24759874.
4. Valdez BC, Wang G, Murray D, Nieto Y, Li Y, Shah J, Turturro F, Wang M, Weber DM, Champlin RE, Qazilbash MH, Andersson BS. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications. Exp Hematol 41(8):719-30, 8/2013. e-Pub 5/2013. PMCID: PMC3769691.
5. Koshy N, Ong MG, Nordberg ML, Turturro F, Cotelingam JD. Oligosecretory biclonal multiple myeloma. J La State Med Soc 165(4):215, 217-8, Jul-Aug, 7/2013. PMID: 24133785.
6. Faria E, Turturro F, Rao P, Matin SF. Malignant Epithelioid Angiomyolipoma: tumor and metabolic response to everolimus as evaluated with positron emission tomography. Genitorin Cancer 11. e-Pub 6/2013.
7. Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 119(19):4375-82, 5/2012. e-Pub 3/2012. PMID: 22422823.
8. Friday E, Koshy N, Bhanderi V, Turturro F. Thioredoxin-interacting protein and chronic lymphocytic leukemia. Leuk Lymphoma 53(3):492-4, 3/2012. PMID: 21916829.
9. Vaira S, Friday E, Scott K, Conrad S, Turturro F. Wnt/β-catenin signaling pathway and thioredoxin-interacting protein (TXNIP) mediate the "glucose sensor" mechanism in metastatic breast cancer-derived cells MDA-MB-231. J Cell Physiol 227(2):578-86, 2/2012. PMID: 21448924.
10. Friday E, Oliver R, Welbourne T, Turturro F. Glutaminolysis and glycolysis regulation by troglitazone in breast cancer cells: relationship to mitochondrial membrane Potential. J Cell Physiol 226(2):511-9, 2/2011. PMID: 20683912.
11. Friday E, Ledet J, Turturro F. Response to dexamethasone is glucose-sensitive in multiple myeloma cell lines. J Exp Clin Cancer Res 30:81, 2011. e-Pub 9/2011. PMCID: PMC3182135.
12. Turturro F, Leary C, Stephens J, Veillon D, Lowery-Nordberg M. Caution using hypomethylating agents in myelodysplasia or myeloid leukemia with complex cytogenetics. J Clin Oncol 28(22):e380-1, 8/1/2010. e-Pub 5/10/2010. PMID: 20458054.
13. Oliver R, Friday E, Turturro F, Welbourne T. Troglitazone regulates anaplerosis via a pull/push affect on glutamate dehydrogenase mediated glutamate deamination in kidney-derived epithelial cells: implications for the Warburg effect. Cell Physiol Biochem 26(4-5):619-28, 2010. e-Pub 10/2010. PMID: 21063099.
14. Turturro F. Beyond the Knudson's hypothesis in von Hippel-Lindau (VHL) disease-proposing vitronectin as a "gene modifier". J Mol Med (Berl) 87(6):591-3, 6/2009. PMID: 19352613.
15. Oliver R, Friday E, Turturro F, Welbourne T. Troglitazone induced cytosolic acidification via extracellular signal-response kinase activation and mitochondrial depolarization: complex I proton pumping regulates ammoniagenesis in proximal tubule-like LLC-PK1 cells. Cell Physiol Biochem 22(5-6):475-86, 2008. e-Pub 12/2008. PMID: 19088429.
16. Turturro F. Update on front-line therapy for follicular lymphoma: chemo-immunotherapy with rituximab and survival. Expert Rev Anticancer Ther 7(7):959-65, 7/2007. PMID: 17627454.
17. Turturro F, Von Burton G, Friday E. Hyperglycemia-induced thioredoxin-interacting protein expression differs in breast cancer-derived cells and regulates paclitaxel IC50. Clin Cancer Res 13(12):3724-30, 6/2007. PMID: 17575238.
18. Turturro F, Driscoll M, Friday E, Welbourne T. ALK-mediated Na+/H+ exchanger-dependent intracellular alkalinization: does it matter for oncogenesis? Haematologica 92(5):706-7, 5/2007. PMID: 17488701.
19. Turturro F, Oliver R, Friday E, Nissim I, Welbourne T. Troglitazone and pioglitazone interactions via PPAR-gamma-independent and -dependent pathways in regulating physiological responses in renal tubule-derived cell lines. Am J Physiol Cell Physiol 292(3):C1137-46, 3/2007. e-Pub 10/2006. PMID: 17065204.
20. Dang NH, Pro B, Hagemeister FB, Samaniego F, Jones D, Samuels BI, Rodriguez MA, Goy A, Romaguera JE, McLaughlin P, Tong AT, Turturro F, Walker PL, Fayad L. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 136(3):439-47, 2/2007. PMID: 17233846.
21. Turturro F. Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther 7(1):11-7, 1/2007. PMID: 17187516.
22. Chintapalli N, Lowery Nordberg M, Hiemenz J, Turturro F. Acute Myeloid Leukemia disguised as a solid tumor. Clinical Leukemia 1:198, 2007.
23. Turturro F, Friday E, Welbourne T. Hyperglycemia regulates thioredoxin-ROS activity through induction of thioredoxin-interacting protein (TXNIP) in metastatic breast cancer-derived cells MDA-MB-231. BMC Cancer 7:96, 2007. e-Pub 6/2007. PMCID: PMC1906826.
24. Friday E, Oliver R, Welbourne T, Turturro F. Role of epidermal growth factor receptor (EGFR)-signaling versus cellular acidosis via Na+/H+ exchanger1(NHE1)-inhibition in troglitazone-induced growth arrest of breast cancer-derived cells MCF-7. Cell Physiol Biochem 20(6):751-62, 2007. PMID: 17982257.
25. Perrotti D, Turturro F, Neviani P. BCR/ABL, mRNA translation and apoptosis. Cell Death Differ 12:534, 2005.
26. Turturro F, Lawson M, Friday E, Welbourne T. Targeting Na+/H+ exchanger: an old concept with new perspective in the treatment of hematological malignancies. Leuk Res 31:1449, 2005.
27. Oliver R, Friday E, Turturro F. Lacy A, Welbourne T. Troglitazone’s rapid activation of ERK1/2 induces cellular acidosis and ammoniogenesis in LLC-PK1-F+ cells. Am J Physiol Renal Physiol 288:F1257, 2005.
28. Pulford K, Morris SW, Turturro F. Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol 199:330, 2004.
29. Sallah S, Husain A, Sigounas V, Wan J, Turturro F, Sigounas G, Nguyen NP. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. Clin Cancer Res 10:7238, 2004.
30. K Pulford, L Lamant, E Espinos, Q Jiang, L Xue, F Turturro, G Delsol, SW Morris. The emerging normal and disease related roles of anaplastic lymphoma kinase. Cell Mol Life Sc 61:2939, 2004.
31. Welbourne TC, Friday E, Fowler R, Turturro F. Troglitazone acts by PPARgamma and PPARgamma-independent pathways on LLC-PK1-F+ acid-base metabolism. Am J Physiol Renal Physiol 286:F100, 2004.
32. Turturro F, Friday E, Fowler R, Surie D, Welbourne T. Troglitazone acts on cellular pH and DNA synthesis through a PPAR-independent mechanism in breast cancer-derived cell lines. Clin Cancer Res 10:7022, 2004.
33. Turturro F, Seth P. Prolonged adenovirus-mediated expression of p27Kip1 unveils unexpected effects of this protein on the phenotype of SUDHL-1 cells derived from t(2;5) anaplastic large cell lymphoma. Leuk Res 27:329, 2003.
34. Turturro. Recombinant adenovirus-mediated cytotoxic gene therapy of lymphoproliferative disorders: is CAR important for the vector to ride? Gene Therapy 10:100, 2003.
35. Turturro F, Arnold MD, Frist AY, Seth P. Effects of adenovirus-mediated expression of p27Kip1, p21Waf1 and p16INK4A in cell lines derived from t(2;5) anaplastic large cell lymphoma and Hodgkin’s Disease. Leuk Lymphoma 6:1323, 2002.
36. Turturro F, Arnold MD, Frist AY,Pulford K. Model of inhibition of the NPM-ALK kinase activity by herbimycin A. Clin Cancer Res 8:240, 2002.
37. Turturro F. Recombinant Adenoviral-mediated Cytotoxic Gene Therapy and Lymphoproliferative Disorders: Analysis Based on Pharmacodynamics. Curr Drug Targets Immune Endocr & Metabolic Disord 2:109, 2002.
38. Turturro F, Frist AY, Arnold MD,Seth P, Pulford K. Biochemical differences between SUDHL-1 and KARPAS 299 cells derived from t(2;5)-positive anaplastic large cell lymphoma are responsible for the different sensitivity to the antiproliferative effect of p27. Oncogene, 20:4466, 2001.
39. Turturro F, Frist AY, Arnold MD, Pal A, Cook GA, Seth P. Comparison of the effects of recombinant adenovirus-mediated expression of wild type p53 and p27Kip1 on cell cycle and apoptosis in SUDHL-1 cells derived from anaplastic large cell lymphoma. Leukemia 15:1225, 2001.
40. Turturro F, Heineke HL, Drevyanko TF, Link CJ. Seth P. Adenoviral p53-mediated gene therapy of anaplastic large cell lymphoma with t(2;5) in a nude mouse model. Gene Therapy 7:930, 2000.
41. Turturro F, Seth P, Link CJ. In vitro adenoviral vector p53-mediated transduction and killing correlates with expression of coxsackie-adenovirus receptor (CAR) and 5 integrin in SUDHL-1 cells derived from anaplastic large cell lymphoma. Clin Cancer Res 6:185, 2000.
42. Meeker TC, Lay LT, Wroblewski JM, Turturro F, Li Z, Seth P. Adenoviral vectors efficiently target cell lines derived from selected lymphocytic malignancies, including anaplastic large cell lymphoma and Hodgkin’s disease. Clin Cancer Res 3:357, 1997.
43. Turturro F, Tritz DM, Doukas M. Extrahepatic manifestations of hepatitis C virus: association with monoclonal gammopathies. Ann Int Med 125(4):345, 1996.
44. Shih WJ, Turturro F, Stipp V, De Simone P. Ring appearance on Tc-99m MIBI thoracic SPECTs and increased uptake on Tc-99m HMDP thoracic SPECTs in a pulmonary mass of small cell carcinoma. Ann Nucl Med 10(4):425, 1996.
45. Capurso, FR, Turturro F, Colacicco AM, Crecchio C, Pepe G. APO-CII deficiency type. Eur J Epidem 8(2):64, 1992.
46. Capurso AM, Mogavero F, Resta M, DiTommaso R, Taverniti, Turturro F, La Rosa M, Marcovina S, Catapano A. Apolipoprotein CII Deficiency: detection of immunoreactive apolipoprotein CII in the intestinal mucosa of two patients. J Lip Res 29:703, 1988.
47. Turturro F, Heibig J, Chan L, Gotto AM, Ghiselli G. A complex Hind III polymorphism in the human apoprotein (apo) B gene. Nucl Ac Res 15:9618, 1987.

Abstracts

1. Patel KK, Orlowski RZ, Weber DM, Wang M, Thomas SK, Shah JJ, Turturro F, Alexanian R, Delasalle K. Prognostic value of serum lactate dehydrogenase in symptomatic multiple myeloma. ASCO Meeting, 2012.
2. Friday R, Oliver R, Welbourne T, Turturro F. Directing glutamine and glucose metabolism with troglitazone and EGCG limits MCF-7 cell growth. In: Proceedings of 101st Annual Meeting of the American Association for Cancer Research, 2010.
3. Friday E, Koshy N, Bhanderi V, Turturro F. Effect of antioxidant N-Acetylcystein treatment on the phenotype of the TCL-1 transgenic mouse model of B-CLL through Reactive Oxygen Species (ROS) regulation. Blood, 2010.
4. Vaira S, Friday R, Scott K, Conrad S, Mills G, Turturro F. Hyperglycemia modulates the Wnt/b-catenin signaling pathway in breast cancer. Proceedings of 101st Annual Meeting of the American Association for Cancer Research, 2010.
5. 42. Devarakonda SS, Nair BS, Gonzales RA, Shi r, Koshy N, Burton G, Glass J, Turturro F. Impact of health care funding on overall survival of patients with multiple myeloma and monoclonal gammopathy of uncertain significance. Blood,, 2010.
6. Koshy N, Friday R, Bhanderi V, Turturro F. Thioredoxin-interacting protein-reactive oxygen species (TXNIP/ROS) relationship defines a stress response gene signature in patients with CLL. In: Proceedings of 101st Annual Meeting of the American Association for Cancer Research, 2010.
7. Stuart RK, Ravandi K, Cripe LD, Maris MB, Cooper MA, Dakhil SR, Stone RM, Turturro F, Fox JA, Michelson G. Voreloxin single-agent treatment of older patients (60 years or older) with previously untreated acute myeloid leukemia: Final results from a phase II study with three schedules. J Clin Oncol, 2010.
8. Ravandi F, Stuart R, Maris M, Stone R, Cripe L, Cooper M, Strickland S, Turturro F, Stock W, Mahadocon K, Fox J, Michelson G, Berman C. A phase 2 study of voroloxin as single agent therapy for elderly patients with newly diagnosed acute myeloid leukemia. ASCO Annual Meeting Proceedings, 2009.
9. Ravandi F, Kantarijian HM, Cripe LD, Maris M, Cooper M, Dakhil S, Stone RM, Turturro F, Chen T, Mahadocon K, Fox J, Bernan C, Michelson GC, and Stuart RK. A phase II dose regimen optimization study of three schedules of voreloxin as single agent therapy for elderly patients with newly diagnosed acute myeloid leukemia. Blood, 2009.
10. Friday E, Kaskas N, Ledet J, Turturro F. Effect of vorinostat based combination on TXNIP expression and reactive oxygen species (ROS) regulation in follicular lymphoma cell line. Proc Am Assoc Cancer Res, 2009.
11. Friday E, Oliver RIII, Welbourne T, Turturro F. Enhanced acidogenesis and glutaminolysis accompanies ERK-dependent mitochondrial depolarization in troglitazone treated breast cancer cells. Proc Am Assoc Cancer Res, 2009.
12. 31. Friday RE, Turturro F, Mailhes JB. Cumulative dose of Bortezomib induces chromosome abnormalities in mouse bone marrow cells in vivo. Proc Am Assoc Cancer Res, 2008.
13. Friday RE, Wendling CV, Ledet J, Turturro F. Effects of hypeglycemia and dexamethasone on expression of thiorodoxin-interacting protein (TXNIP) expression and reactive oxygen species (ROS) in multiple myeloma-derived cell lines. Proc Am Assoc Cancer Res, 2008.
14. Steffan JJ, Duhon D, Welbourne T, Turturro F, Cardelli JA. Cardelli JA. HGF induction of lysosome redistribution and invasion of DU-145 prostate cancer cells depends on the activity of the sodium-proton exchanger, NHE1. Proc Am Assoc Cancer Res, 2007.
15. 29. Friday E, Oliver R, III, Welbourne T, Turturro F. EGFR signaling vs cellular acidosis in TRO-induced growth inhibition in MCF-7 breast cancer cells. Proc Am Assoc Cancer Res, 2007.
16. Turturro F, Glass J, Mills G, Ranhua S. Meta-analysis of the tumor response in patients treated with rituximab either in combination with chemotherapy or with treatment following chemotherapy in CD20+ B-cell lymphomas. Proc Am Assoc Cancer Res, 2007.
17. Welbourne T, Turturro F, Oliver R, III, Friday E. Metabolic acidosis and TRO reduce citrate excretion and increase bicarbonate and ammonium excretion. FASEB J, 2007.
18. 24. Oliver RE, Kaur P, Turturro F, Friday E, Welbourne T. P-ERK activation by extracellular or intracellular acidosis slows NHE3-mediated acid extrusion and activates ammoniagenesis in LLC-PK1-F+ cells. FASEB J, 2007.
19. 2Turturro F, Oliver R, III, Welbourne T, Friday E. . Role of EGFR signaling and GADD45 activation vs cellular acidosis in TRO-induced growth inhibition in breast cancer cells. FASEB J, 2007.
20. Turturro F, Friday E. The response of thioredoxin-interacting protein (TXNIP) to hyperglycemia differs in breast cancer-derived cells and correlates with the response to paclitaxel. Proc Am Assoc Cancer Res, 2007.
21. 23. Turturro F, Friday E, Oliver R, III, Welbourne T. Dual PPARgamma/alpha agonist has potent anticancer activity. FASEB J, 2006.
22. 21. Friday E, Welbourne T, Olliver R III, Turturro F. Simvastatin combined with troglitazone decreases proliferation by increasing cellular acidosis in MCF-7 breast cancer cell line. Proc Am Assoc Cancer Res, 2006.
23. Welbourne CT, Friday E, Oliver R, III, Turturro F. Troglitazone enhances PEPCK expression via ERK activation in proximal tubule-like LLC-PK1-F+ cells. FASEB J, 2006.
24. 20. M Lilly, F Kuriakose, F Turturro, J Berdeja, A Kerr, A Surendranathan, J Black, A Frankel. A phase II study of denileukin diftitox (ONTAK) in patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. 41ST Annual Meeting, 2005.
25. E Friday, A Veluvolu, J Butler, T Welbourne, F Turturro. Inhibition of heat shock protein 90 (Hsp90) sensitizes HER2-negative breast cancer derived MDA-MD-231 cell line to cytotoxic effect of troglitazone (TRO). Proceedings of the American Association for Cancer Research, 2005.
26. E Friday, R Oliver III, T Welbourne, F Turturro. Troglitazone’s rapid activation of ERK1/2 induces cellular acidosis in MCF-7 breast cancer cells. Proceedings of the American Association for Cancer Research, 2005.
27. M Lawson, E Friday, J Glass, F Turturro. Analysis of the correlation between the expression of VEGF and 5 and the ratio of eukaryotic initiation factor 4E (eif4E)/phosphorylated 4E-binding protein 1 (4EBP-1) level in hematopoietic derived cell lines. Proceedings of the American Association for Cancer Research, 2004.
28. E Friday, T Welbourne, R Fowler, F Turturro. Troglitazone exerts PPAR- independent mediated action on cellular pH (pHi) in breast cancer-derived cell lines. Proceedings of the American Association for Cancer Research, 2004.
29. L Ferdinand, JM van Wert, R Shi, F Turturro, C Nopajaroonsri, A Lurie, R Singal. Promoter methylation of glutathione S-transferase P1 (GSTP1), endothelin-B receptor (EBR), and RASSF1A genes in prostrate cancer. Proceedings of the American Association for Cancer Research, 2003.
30. PK Seth, A.Pal, G Cook, N Curl, M Essmann, W Zhao, M Kobayashi, M Hosokawa, N Habib, B Larsen, T Breithaupt, F Turturro. Cancer gene therapy using adenoviral vectors expressing tumor suppressor genes: pre-clinical modeling. Proceedings of the American Association for Cancer Research, 2002.
31. Turturro F. The response to 17-allylamino-17-demethoxygeldanamycin (17-AAG) is cell dependent and mediated by different mechanisms in cells derived from t(2;5)-positive anaplastic large cell lymphoma. Proceedings of the American Association for Cancer Research, 2002.

Book Chapters

1. Turturro F. ALK+ and ALK- anaplastic large cell lymphoma. In: T-cell malignancies: recent development and novel therapeutic approaches, 2010.
2. Capurso, AM Mogavero M DiTommaso, F Resta, R Taverniti, F Turturro, S Palmisano. Binding of Apolipoproteins to arterial thrombi. In: Excerpta Medica, 1989.
3. F Turturro, J Heibig, G Ghiselli, AM Gotto Jr. RFLPs of Apo-B gene. In: Human apolipoprotein mutants. From gene structure to phenotypic expression, 1989.
4. G Ghiselli, J Heibig, F Turturro, AM Gotto, E Wittels. Apo I and Apo II metabolism and coronary artery disease. In: Drugs affecting lipid metabolism, 1987.
5. Capurso, AL Catapano, GL Mills, F Resta, R Taverniti, AM Mogavero, M DiTommaso, F Turturro, D Ciancia, G Siciliani. Formation of HDL like particles following chylomicrons lipoplysis. In: High density lipoproteins:Physiopathological aspects and clinical significance, 1987.
6. Capurso AM Mogavero, G Siciliani, F Resta, R Taverniti, FTurturro. Apoproteins and alpha-1-antitrypsin in human bile. In: Recent advances in bile acid research: New York, 1985.
7. Capurso AM, Mogavero R, Taverniti R, Resta F, Siciliani G, Turturro F, Palmisano S. Lipid and apoprotein modifications induced by Fenofibrate. In: S.Lenzi andG.C.Descovich, eds. Atherosclerosis and Cardiovascular Disease. In: Proceedings of the 5th International Meeting on Atherosclerosis, 1984.

Last updated: 11/10/2014